Agile Therapeutics traded at $0.37 this Tuesday April 9th, decreasing $0.03 or 6.40 percent since the previous trading session. Looking back, over the last four weeks, Agile Therapeutics lost 48.64 percent. Over the last 12 months, its price fell by 96.43 percent. Looking ahead, we forecast Agile Therapeutics to be priced at 0.36 by the end of this quarter and at 0.33 in one year, according to Trading Economics global macro models projections and analysts expectations.
Agile Therapeutics, Inc. is a women’s healthcare company. The Company’s approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla uses its transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability, which may help support compliance. Its product pipeline consists of two types of product candidates: Twirla line extensions and other transdermal contraceptive product candidates. These potential product candidates are designed to address market needs of additional non-daily contraceptive options. Its Twirla line extensions include AG200-15 Extended Regimen (ER), AG200-15 SmP, AG200-15 ER SmP, and AG890, a P-only contraceptive patch.